The EIF2AK1 Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the 786-O human clear cell renal cell carcinoma line, designed to disrupt the EIF2AK1 gene and abolish its expression. This heterogeneous pool of knockout cells serves as a powerful loss-of-function model for studying the heme-regulated eIF2?? kinase HRI (EIF2AK1) within a relevant epithelial adenocarcinoma background without the confounding effects of clonal selection.
The parental 786-O cell line was originally established from a primary clear cell renal cell carcinoma of a 58-year-old male patient and is extensively utilized in renal cancer research. These cells retain characteristic features of renal cell carcinoma, including VHL deficiency, making them a well-suited platform for dissecting stress signaling pathways that influence tumor growth, survival, and drug sensitivity.
EIF2AK1 functions as a sensor of heme deprivation and diverse stress stimuli, including oxidative stress, heat shock, mitochondrial dysfunction, and nitric oxide, and it phosphorylates the ?? subunit of eukaryotic initiation factor 2 (eIF2??) at serine 51. This phosphorylation event suppresses global cap-dependent protein synthesis while selectively increasing translation of ATF4, a transcription factor that drives expression of CHOP, GADD34, and other adaptive genes. EIF2AK1 activity is modulated by direct interaction with heme, as well as by association with HSP90, CDC37, and the negative regulator P58IPK. GADD34, in turn, recruits protein phosphatase 1 (PP1) to dephosphorylate eIF2??, providing negative feedback. This cascade constitutes a key arm of the integrated stress response (ISR) that governs cellular adaptation to stress and recovery.
In the 786-O renal cell carcinoma background, the EIF2AK1 knockout disrupts a critical node of the ISR, allowing researchers to uncouple heme-regulated translational control from the activities of other eIF2?? kinases such as PERK, GCN2, and PKR. This model is particularly valuable for dissecting how tumor cells modulate protein synthesis in response to metabolic challenges, hypoxia, or therapeutic agents that induce proteotoxic stress, and for evaluating the dependency of renal cancer cells on this pathway for survival and proliferation.
This polyclonal knockout product is ideally suited for applications including investigation of integrated stress response mechanisms in renal cell carcinoma, functional dissection of heme-regulated translation, validation of ISR-targeted drug candidates, and exploration of stress signaling crosstalk in clear cell renal carcinoma. Typical downstream assays encompass immunoblotting for phospho-eIF2?? (Ser51) and ATF4 levels to monitor pathway activity, quantitative RT?PCR analysis of ATF4 target genes (e.g., CHOP, GADD34), RNA-sequencing combined with polysome profiling to assess translational changes, cell viability and apoptosis assays under stress conditions such as hemin rescue or pharmacological ISR modulation, and phospho-signaling profiling. For additional information and ordering details, please contact Ascent Research.
